The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial

Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharma...

Descripción completa

Detalles Bibliográficos
Autores principales: ElDash, Rana M., Raslan, Mohamed A., Shaheen, Sara M., Sabri, Nagwa Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167502/
https://www.ncbi.nlm.nih.gov/pubmed/34123370
http://dx.doi.org/10.12688/f1000research.51114.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167502/
https://www.ncbi.nlm.nih.gov/pubmed/34123370
http://dx.doi.org/10.12688/f1000research.51114.1

Ejemplares similares